Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 03-May-22 7:16 PM View:  | Patel Priti Chief Medical Officer | Neoleukin Therapeutics, Inc. (NLTX) | 02-May-22 | Option Sale | 5,538 | $1.22 | $6,748.61 | (46%) 12.0K to 6.46K | |
| 03-May-22 7:16 PM View: | Patel Priti Chief Medical Officer | Neoleukin Therapeutics, Inc. (NLTX) | 30-Apr-22 | Option Exercise | 10,000 | -- | -- | 500% 2.0K to 12.0K | |
| 14-Feb-22 10:00 PM View: | Drachman Jonathan G President and CEO Director | Neoleukin Therapeutics, Inc. (NLTX) | 26-Oct-21 | Gift | 150,000 | -- | -- | (6%) 2.55M to 2.4M | |
| 14-Feb-22 10:00 PM View: | Drachman Jonathan G President and CEO Director | Neoleukin Therapeutics, Inc. (NLTX) | 26-Oct-21 | Gift | 150,000 | -- | -- | 6% 2.4M to 2.55M | |
| 26-Aug-21 7:08 PM View: | Drachman Jonathan G President and CEO Director | Neoleukin Therapeutics, Inc. (NLTX) | 25-Aug-21 | Market Purchase | 50,000 | $6.45 | $322,450.00 | 2% 2.35M to 2.4M | |
| 26-Aug-21 7:08 PM View: | Drachman Jonathan G President and CEO Director | Neoleukin Therapeutics, Inc. (NLTX) | 24-Aug-21 | Market Purchase | 100,000 | $6.11 | $611,100.00 | 4% 2.25M to 2.35M | |
| 17-Jun-21 9:46 PM View: | Walkey Carl Senior Vice President | Neoleukin Therapeutics, Inc. (NLTX) | 16-Jun-21 | Market Sale (Planned) | 600 | $10.19 | $6,114.00 | (< 1%) 1.35M to 1.35M | 1% |
| 11-Jun-21 4:13 PM View: | Walkey Carl Senior Vice President | Neoleukin Therapeutics, Inc. (NLTX) | 09-Jun-21 | Market Sale (Planned) | 650 | $10.82 | $7,035.99 | (< 1%) 1.35M to 1.35M | 2% |
| 09-Jun-21 5:22 PM View: | Walkey Carl Senior Vice President | Neoleukin Therapeutics, Inc. (NLTX) | 08-Jun-21 | Market Sale (Planned) | 600 | $11.00 | $6,600.00 | (< 1%) 1.35M to 1.35M | |
| 07-Jun-21 5:07 PM View: | Walkey Carl Senior Vice President | Neoleukin Therapeutics, Inc. (NLTX) | 04-Jun-21 | Market Sale (Planned) | 600 | $10.00 | $6,000.00 | (< 1%) 1.35M to 1.35M | 3% |
| 07-Jun-21 5:06 PM View: | Drachman Jonathan G President and CEO Director | Neoleukin Therapeutics, Inc. (NLTX) | 04-Jun-21 | Market Purchase | 10,000 | $9.61 | $96,082.00 | < 1% 2.24M to 2.25M | < 1% |
| 07-Jun-21 5:06 PM View: | Drachman Jonathan G President and CEO Director | Neoleukin Therapeutics, Inc. (NLTX) | 03-Jun-21 | Market Purchase | 40,000 | $9.48 | $379,272.00 | 2% 2.2M to 2.24M | 2% |
| 26-May-21 7:37 PM View: | Walkey Carl Senior Vice President | Neoleukin Therapeutics, Inc. (NLTX) | 26-May-21 | Market Sale (Planned) | 600 | $10.00 | $6,000.00 | (< 1%) 1.36M to 1.35M | 1% |
| 21-May-21 5:24 PM View: | Walkey Carl Senior Vice President | Neoleukin Therapeutics, Inc. (NLTX) | 19-May-21 | Market Sale (Planned) | 600 | $10.63 | $6,378.00 | (< 1%) 1.36M to 1.36M | 2% |
| 12-May-21 8:53 PM View: | Walkey Carl Senior Vice President | Neoleukin Therapeutics, Inc. (NLTX) | 12-May-21 | Market Sale (Planned) | 1,200 | $11.09 | $13,308.00 | (< 1%) 1.36M to 1.35M | (3%) |
| 06-May-21 5:28 PM View: | Walkey Carl Senior Vice President | Neoleukin Therapeutics, Inc. (NLTX) | 05-May-21 | Market Sale (Planned) | 1,200 | $11.30 | $13,560.00 | (< 1%) 1.36M to 1.36M | (11%) |
| 30-Apr-21 5:52 PM View: | Walkey Carl Senior Vice President | Neoleukin Therapeutics, Inc. (NLTX) | 28-Apr-21 | Market Sale (Planned) | 2,400 | $12.58 | $30,192.00 | (< 1%) 1.36M to 1.36M | (3%) |
| 27-Apr-21 7:59 PM View: | Walkey Carl Senior Vice President | Neoleukin Therapeutics, Inc. (NLTX) | 26-Apr-21 | Market Sale (Planned) | 600 | $13.00 | $7,800.00 | (< 1%) 1.36M to 1.36M | (< 1%) |
| 22-Apr-21 5:11 PM View: | Walkey Carl Senior Vice President | Neoleukin Therapeutics, Inc. (NLTX) | 21-Apr-21 | Market Sale (Planned) | 1,800 | $11.98 | $21,564.00 | (< 1%) 1.36M to 1.36M | (3%) |
| 16-Apr-21 10:00 PM View: | Walkey Carl Senior Vice President | Neoleukin Therapeutics, Inc. (NLTX) | 14-Apr-21 | Market Sale (Planned) | 1,800 | $12.22 | $21,996.00 | (< 1%) 1.36M to 1.36M | < 1% |
| 08-Apr-21 7:06 PM View: | Walkey Carl Senior Vice President | Neoleukin Therapeutics, Inc. (NLTX) | 07-Apr-21 | Market Sale (Planned) | 1,800 | $12.02 | $21,636.00 | (< 1%) 1.37M to 1.36M | (1%) |
| 06-Apr-21 8:37 PM View: | Walkey Carl Senior Vice President | Neoleukin Therapeutics, Inc. (NLTX) | 05-Apr-21 | Market Sale (Planned) | 600 | $13.00 | $7,800.00 | (< 1%) 1.37M to 1.37M | (< 1%) |
| 02-Apr-21 5:21 PM View: | Walkey Carl Senior Vice President | Neoleukin Therapeutics, Inc. (NLTX) | 31-Mar-21 | Market Sale (Planned) | 1,800 | $11.96 | $21,528.00 | (< 1%) 1.37M to 1.37M | 2% |
| 24-Mar-21 6:48 PM View: | Walkey Carl Senior Vice President | Neoleukin Therapeutics, Inc. (NLTX) | 24-Mar-21 | Market Sale (Planned) | 1,800 | $11.95 | $21,515.90 | (< 1%) 1.37M to 1.37M | < 1% |
| 24-Mar-21 6:48 PM View: | Walkey Carl Senior Vice President | Neoleukin Therapeutics, Inc. (NLTX) | 22-Mar-21 | Market Sale (Planned) | 600 | $12.00 | $7,200.00 | (< 1%) 1.37M to 1.37M | < 1% |
| 18-Mar-21 8:45 PM View: | Walkey Carl Senior Vice President | Neoleukin Therapeutics, Inc. (NLTX) | 17-Mar-21 | Market Sale (Planned) | 1,200 | $11.36 | $13,632.00 | (< 1%) 1.37M to 1.37M | < 1% |
| 18-Mar-21 8:44 PM View: | Ho Robert Chief Financial Officer | Neoleukin Therapeutics, Inc. (NLTX) | 17-Mar-21 | Market Option Sale | 6,497 | $11.01 | $71,556.00 | (23%) 28.0K to 21.5K | |
| 18-Mar-21 8:44 PM View: | Ho Robert Chief Financial Officer | Neoleukin Therapeutics, Inc. (NLTX) | 16-Mar-21 | Option Exercise | 25,000 | -- | -- | 833% 3.0K to 28.0K | |
| 11-Mar-21 4:14 PM View: | Walkey Carl Senior Vice President | Neoleukin Therapeutics, Inc. (NLTX) | 10-Mar-21 | Market Sale (Planned) | 1,800 | $11.97 | $21,540.10 | (< 1%) 1.37M to 1.37M | 2% |
| 04-Mar-21 6:52 PM View: | Walkey Carl Senior Vice President | Neoleukin Therapeutics, Inc. (NLTX) | 03-Mar-21 | Market Sale (Planned) | 1,800 | $11.87 | $21,360.10 | (< 1%) 1.38M to 1.37M | (1%) |
| 25-Feb-21 8:17 PM View: | Walkey Carl Senior Vice President | Neoleukin Therapeutics, Inc. (NLTX) | 25-Feb-21 | Market Sale (Planned) | 600 | $13.00 | $7,800.00 | (< 1%) 1.38M to 1.38M | 4% |
| 25-Feb-21 8:17 PM View: | Walkey Carl Senior Vice President | Neoleukin Therapeutics, Inc. (NLTX) | 24-Feb-21 | Market Sale (Planned) | 1,800 | $12.14 | $21,852.00 | (< 1%) 1.38M to 1.38M | (2%) |
| 18-Feb-21 4:20 PM View: | Walkey Carl Senior Vice President | Neoleukin Therapeutics, Inc. (NLTX) | 17-Feb-21 | Market Sale (Planned) | 2,400 | $12.70 | $30,480.00 | (< 1%) 1.38M to 1.38M | 2% |
| 12-Feb-21 4:23 PM View: | Walkey Carl Senior Vice President | Neoleukin Therapeutics, Inc. (NLTX) | 10-Feb-21 | Market Sale (Planned) | 3,000 | $14.20 | $42,600.00 | (< 1%) 1.38M to 1.38M | 12% |
| 09-Feb-21 4:41 PM View: | Walkey Carl Senior Vice President | Neoleukin Therapeutics, Inc. (NLTX) | 05-Feb-21 | Market Sale (Planned) | 600 | $14.00 | $8,400.00 | (< 1%) 1.38M to 1.38M | 11% |
| 05-Feb-21 4:51 PM View: | Walkey Carl Senior Vice President | Neoleukin Therapeutics, Inc. (NLTX) | 03-Feb-21 | Market Sale (Planned) | 2,400 | $13.23 | $31,752.00 | (< 1%) 1.39M to 1.38M | 6% |
| 23-Dec-20 7:31 PM View: | Baker Bros Advisors LLC Director | Neoleukin Therapeutics, Inc. (NLTX) | 07-Jul-20 | Market Purchase | 424,000 | $15.25 | $6,466,000.00 | 12% 3.4M to 3.83M | (18%) |
| 06-Apr-20 7:04 PM View: | Redmile Group, LLC 10% Owner | Neoleukin Therapeutics, Inc. (NLTX) | 02-Apr-20 | Market Sale | 9,834 | $11.31 | $111,214.00 | (< 1%) 4.05M to 4.04M | (10%) |
| 06-Apr-20 7:04 PM View: | Redmile Group, LLC 10% Owner | Neoleukin Therapeutics, Inc. (NLTX) | 02-Apr-20 | Market Purchase | 39,300 | $11.37 | $446,958.00 | < 1% 4.01M to 4.05M | 9% |
| 06-Apr-20 7:04 PM View: | Redmile Group, LLC 10% Owner | Neoleukin Therapeutics, Inc. (NLTX) | 01-Apr-20 | Market Purchase | 42,500 | $11.10 | $471,630.00 | 1% 3.98M to 4.02M | 12% |
| 06-Apr-20 7:04 PM View: | Redmile Group, LLC 10% Owner | Neoleukin Therapeutics, Inc. (NLTX) | 01-Apr-20 | Market Sale | 9,834 | $11.08 | $108,940.00 | (< 1%) 4.02M to 4.01M | (12%) |
| 06-Apr-20 7:04 PM View: | Redmile Group, LLC 10% Owner | Neoleukin Therapeutics, Inc. (NLTX) | 31-Mar-20 | Market Purchase | 30,000 | $10.31 | $309,388.00 | < 1% 3.95M to 3.98M | 21% |
| 06-Apr-20 7:04 PM View: | Redmile Group, LLC 10% Owner | Neoleukin Therapeutics, Inc. (NLTX) | 30-Mar-20 | Market Purchase | 32,500 | $9.94 | $322,910.00 | < 1% 3.92M to 3.95M | 25% |
| 06-Apr-20 7:04 PM View: | Redmile Group, LLC 10% Owner | Neoleukin Therapeutics, Inc. (NLTX) | 27-Mar-20 | Market Purchase | 50,000 | $9.21 | $460,395.00 | 1% 3.87M to 3.92M | 35% |
| 20-Dec-19 5:16 PM View: | Baker Bros Advisors LLC Director | Neoleukin Therapeutics, Inc. (NLTX) | 20-Dec-19 | Disposition | 10,925,500 | -- | -- | (38%) 28.65M to 17.73M | |
| 20-Dec-19 5:16 PM View: | Baker Bros Advisors LLC Director | Neoleukin Therapeutics, Inc. (NLTX) | 20-Dec-19 | Private Purchase | 3,017,540 | $8.40 | $25,347,400.00 | 12% 25.63M to 28.65M | |
| 20-Dec-19 6:53 PM View: | Drachman Jonathan G President and CEO Director | Neoleukin Therapeutics, Inc. (NLTX) | 20-Dec-19 | Private Purchase | 119,047 | $8.40 | $999,995.00 | 6% 2.08M to 2.2M | |
| 20-Dec-19 6:53 PM View: | Drachman Jonathan G President and CEO Director | Neoleukin Therapeutics, Inc. (NLTX) | 12-Nov-19 | Conversion | 1,261,600 | -- | -- | 152% 830.66K to 2.09M | |
| 20-Dec-19 6:53 PM View: | Drachman Jonathan G President and CEO Director | Neoleukin Therapeutics, Inc. (NLTX) | 12-Nov-19 | Conversion | 12,616 | -- | -- | (< 1%) 2.09M to 2.08M | |
| 11-Sep-19 5:39 PM View: | Drachman Jonathan G See Remarks Director | Neoleukin Therapeutics, Inc. (NLTX) | 11-Sep-19 | Market Purchase | 136,436 | $3.30 | $449,898.00 | 30% 455.42K to 591.86K | 278% |
